Certara (NASDAQ:CERT) Stock Price Down 7% – Here’s Why

Certara, Inc. (NASDAQ:CERT)’s stock price was down 7% on Wednesday . The company traded as low as $6.65 and last traded at $6.6650. 1,767,528 shares were traded during mid-day trading, a decline of 52% from the average daily volume of 3,701,465 shares. The stock had previously closed at $7.17.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on the stock. BMO Capital Markets decreased their target price on shares of Certara from $7.00 to $6.00 and set a “market perform” rating for the company in a report on Tuesday, May 12th. Robert W. Baird cut their price target on Certara from $7.00 to $6.00 and set a “neutral” rating for the company in a research note on Tuesday, May 12th. Craig Hallum decreased their target price on shares of Certara from $10.00 to $8.00 and set a “hold” rating on the stock in a research note on Tuesday, May 12th. Morgan Stanley decreased their target price on Certara from $11.00 to $10.00 and set an “equal weight” rating on the stock in a research note on Tuesday, May 12th. Finally, Barclays dropped their price objective on shares of Certara from $8.00 to $6.50 and set an “equal weight” rating for the company in a report on Tuesday, May 12th. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $8.85.

Certara Price Performance

The company has a current ratio of 1.88, a quick ratio of 1.88 and a debt-to-equity ratio of 0.28. The company has a market capitalization of $1.04 billion, a PE ratio of -66.75 and a beta of 1.46. The stock’s 50-day moving average is $5.66 and its two-hundred day moving average is $6.82.

Certara (NASDAQ:CERT) last released its earnings results on Monday, May 11th. The company reported $0.09 EPS for the quarter, missing analysts’ consensus estimates of $0.11 by ($0.02). Certara had a negative net margin of 3.60% and a positive return on equity of 3.52%. The business had revenue of $106.92 million for the quarter, compared to the consensus estimate of $106.13 million. During the same period in the prior year, the company posted $0.14 EPS. The company’s quarterly revenue was up .8% compared to the same quarter last year. Certara has set its FY 2026 guidance at 0.350-0.410 EPS. On average, equities analysts predict that Certara, Inc. will post 0.24 EPS for the current year.

Institutional Trading of Certara

A number of large investors have recently modified their holdings of CERT. Osaic Holdings Inc. grew its holdings in Certara by 50.7% in the second quarter. Osaic Holdings Inc. now owns 3,491 shares of the company’s stock worth $41,000 after purchasing an additional 1,175 shares during the last quarter. Corient Private Wealth LLC grew its holdings in shares of Certara by 11.7% during the second quarter. Corient Private Wealth LLC now owns 12,362 shares of the company’s stock valued at $144,000 after buying an additional 1,295 shares during the last quarter. Central Pacific Bank Trust Division increased its holdings in shares of Certara by 8.7% in the second quarter. Central Pacific Bank Trust Division now owns 19,460 shares of the company’s stock valued at $127,000 after purchasing an additional 1,558 shares during the period. Treasurer of the State of North Carolina raised its position in Certara by 2.9% during the 2nd quarter. Treasurer of the State of North Carolina now owns 56,628 shares of the company’s stock worth $663,000 after buying an additional 1,597 shares during the last quarter. Finally, Nicolet Advisory Services LLC raised its holdings in shares of Certara by 7.4% during the third quarter. Nicolet Advisory Services LLC now owns 30,608 shares of the company’s stock worth $396,000 after purchasing an additional 2,100 shares during the last quarter. Hedge funds and other institutional investors own 73.96% of the company’s stock.

Certara Company Profile

Certara is a biosimulation software and services company that partners with pharmaceutical, biotechnology and medical device developers to accelerate drug discovery, development and regulatory approval. The company’s platform integrates quantitative pharmacology, real-world evidence, artificial intelligence and machine learning to model and simulate drug behavior across a range of therapeutic areas and patient populations. By applying these mechanistic and data-driven approaches, Certara helps its clients predict clinical outcomes, optimize dosing strategies and streamline decision-making throughout the product lifecycle.

The company’s offerings are divided into software tools and consulting services.